Protagonist Therapeutics Inc. (NASDAQ:PTGX) saw an upside of 10.72% to close Tuesday at $12.70 after adding $1.23 on the day. The 5-day average trading volume is 1,046,780 shares of the company’s common stock. It has gained $12.78 in the past week and touched a new high 2 times within the past 5 days. An average of 857,445 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 892,110.
PTGX’s 1-month performance is 29.99% or $2.61 on its low of $9.98 reached on 12/28/22. The company’s shares have touched a 52-week low of $6.91 and high of $30.42, with the stock’s rally to the 52-week high happening on 01/12/23. YTD, PTGX has achieved 16.41% or $1.79 and has reached a new high 7 times. However, the current price is down -58.25% from the 52-week high price.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
PTGX stock has a beta of 2.08. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 18.01 while the price-to-book (PB) in the most recent quarter is 2.56.
Protagonist Therapeutics Inc.’s quick ratio for the period ended June 29 was 7.50, with the current ratio over the same period at 7.50. The firm’s gross profit as reported stood at $153.2 million against revenue of $27.36 million.
For the quarterly period ending June 29 this year, Protagonist Therapeutics Inc.’s cash and short-term investments amounted to $114.62 million against total debt of $4.8 million. Net income shrunk -8.23% to -$31.23 million, while revenue of -$41.04 million was -31.41% off the previous quarter. Analysts expected PTGX to announce -$0.93 per share in earnings in its latest quarter, but it posted -$0.84, representing a 9.70% surprise. EBITDA for the quarter stood at more than -$31.54 million. PTGX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 38.56 million, with total debt at $4.8 million. Shareholders hold equity totaling $49.2 million.
Let’s look briefly at Protagonist Therapeutics Inc. (PTGX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 68.55% to suggest the stock is trending Neutral, with historical volatility in this time period at 71.30%.
The stock’s 5-day moving average is $11.90, reflecting a +9.01% or $1.05 change from its current price. PTGX is currently trading +29.46% above its 20-day SMA, +45.81% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +64.72% and SMA200 by-48.16%.
Stochastic %K and %D was 53.42% and 49.84% and the average true range (ATR) pointed at 0.76. The RSI (14) points at 67.65%, while the 14-day stochastic is at 83.21% with the period’s ATR at 0.71. The stock’s 9-day MACD Oscillator is pointing at -0.07 and 0.15 on the 14-day charts.
In the most recent analyst report for Protagonist Therapeutics Inc. (NASDAQ: PTGX), JMP Securities launched coverage with a Mkt outperform rating. Analysts offering their rating for PTGX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate PTGX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 6 have offered a “buy” rating.
What is PTGX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $21.00 and a high of $41.00, with their median price target at $35.00. Looking at these predictions, the average price target given by analysts is for Protagonist Therapeutics Inc. (PTGX) stock is $33.50.